Such patients are frequently worried about the risk of developing a second breast cancer, and knowing the HSD3B1 genotype information may add to an individualized risk/benefit discussion, especially when concerns about endocrine therapy adherence arise. This evidence concerns the gene HSD3B1 and breast carcinoma.